International Archives of Allergy and Immunology

Original Paper

Mast Cell Recovery following Chronic Treatment with Compound 48/80

Jaffery G.a · Coleman J.W.b · Huntley J.c · Bell E.B.a

Author affiliations

aImmunology Research Group, School of Biological Sciences, University of Manchester Medical School, Manchester, bDepartment of Pharmacology and Therapeutics, University of Liverpool, cMoredun Research Insitute, Edinburgh, UK

Related Articles for ""

Int Arch Allergy Immunol 1994;105:274–280

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 04, 1994
Accepted: July 14, 1994
Published online: September 03, 2009
Issue release date: 1994

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA

Abstract

Histochemical and functional properties of mast cells (MC) in Brown Norway rats recovering from chronic treatment with the MC secretagogue compound 48/ 80 were examined. In the skin, treatment for 5 days with compound 48/80 resulted in a marked decrease in MC subpopulations defined by differential alcian blue/safranin staining. Both safranin-positive connective tissue MC and alcian blue staining MC were reduced in number. This was accompanied by significant decreases in skin histamine and rat MC serine protease I contents and a loss of specific IgE-mediated passive cutaneous anaphylaxis (PCA) activity. The PCA reaction did not return to normal before 2 months after stopping treatment and only when the numbers of safranin-positive connective tissue MC and skin histamine content reached pretreatment levels. The subepidermal alcian blue staining MC not eliminated by the compound 48/80 treatment were formalin resistant (unlike alcian blue staining mucosal MC of the intestine) and apparently played no role in the PCA response. MC numbers, histamine levels, and rat MC serine protease 1 content of the tongue were similarly decreased by compound 48/80. In contrast, mucosal MC of the gut were unaffected by the secretagogue treatment.

© 1994 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 04, 1994
Accepted: July 14, 1994
Published online: September 03, 2009
Issue release date: 1994

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP